Филтриране по Last updated date SelectСледПредиFrom - To Дата Крайна дата This week This month Last week Last month Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationResearch and developmentMedicine shortagesBiosimilarsSMEAntimicrobial resistanceGovernanceBrexitQuality of medicinesCorporateGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate useCareersMedication errorParallel distributionPRIMEProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety Yes Leave this field blank Filter Резултати (3799) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Leave this field blank EMA recommends approval for use of RoActemra in adults with severe COVID-19 6 December 2021NewsHumanCOVID-19Medicines ICMRA and WHO map out flexibilities used by regulators to respond to the COVID-19 pandemic 3 December 2021NewsHumanCOVID-19MedicinesVaccines Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November - 2 December 2021 3 December 2021NewsHumanCOVID-19PharmacovigilanceReferralsVaccines EMA starts rolling review of Valneva’s COVID-19 vaccine (VLA2001) 2 December 2021NewsHumanCOVID-19Vaccines Increase in manufacturing capacity for COVID-19 vaccine from AstraZeneca 1 December 2021NewsHumanCOVID-19Vaccines Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 25 November 2021NewsHumanCOVID-19Vaccines A vision for use of real-world evidence in EU medicines regulation 24 November 2021NewsHumanCorporate EMA receives application for marketing authorisation for Lagevrio (molnupiravir) for treating patients with COVID 19 23 November 2021NewsHumanCOVID-19Medicines 2011-2020: More than 40% decrease in sales of antimicrobials for use in animals 23 November 2021NewsVeterinaryAntimicrobial resistance EMA evaluating data on booster dose of COVID-19 Vaccine Janssen 22 November 2021NewsHumanCOVID-19Vaccines 1 … 50 51 52 53 54 Page 54 of 380 55 56 57 58 … 380
EMA recommends approval for use of RoActemra in adults with severe COVID-19 6 December 2021NewsHumanCOVID-19Medicines
ICMRA and WHO map out flexibilities used by regulators to respond to the COVID-19 pandemic 3 December 2021NewsHumanCOVID-19MedicinesVaccines
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November - 2 December 2021 3 December 2021NewsHumanCOVID-19PharmacovigilanceReferralsVaccines
EMA starts rolling review of Valneva’s COVID-19 vaccine (VLA2001) 2 December 2021NewsHumanCOVID-19Vaccines
Increase in manufacturing capacity for COVID-19 vaccine from AstraZeneca 1 December 2021NewsHumanCOVID-19Vaccines
Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 25 November 2021NewsHumanCOVID-19Vaccines
A vision for use of real-world evidence in EU medicines regulation 24 November 2021NewsHumanCorporate
EMA receives application for marketing authorisation for Lagevrio (molnupiravir) for treating patients with COVID 19 23 November 2021NewsHumanCOVID-19Medicines
2011-2020: More than 40% decrease in sales of antimicrobials for use in animals 23 November 2021NewsVeterinaryAntimicrobial resistance
EMA evaluating data on booster dose of COVID-19 Vaccine Janssen 22 November 2021NewsHumanCOVID-19Vaccines